Printer Friendly

MGI PHARMA'S SALAGEN(TM) DESIGNATED ORPHAN DRUG FOR SJOGREN'S SYNDROME

MGI PHARMA'S SALAGEN(TM) DESIGNATED ORPHAN DRUG FOR SJOGREN'S SYNDROME
 MINNEAPOLIS, March 9 /PRNewswire/ -- MGI Pharma, Inc. (NASDAQ: MOGN) today announced that it has received notice from the Food and Drug Administration (FDA) granting Salagen(TM) (pilocarpine hydrochloride) orphan drug status for the treatment of xerostomia (dry mouth) and keratoconjunctivitis sicca (dry eye) in Sjogren's syndrome patients. Orphan drug designation provides a drug seven years market exclusivity following approval by the FDA.
 Sjogren's Syndrome is a chronic condition in which the function of the lacrimal glands in the eye and the salivary glands and mucus- secreting tissue in the mouth and throat is decreased, resulting in discomfort, pain, visual problems, and difficulties eating, sleeping and speaking.
 Dr. Kenneth F. Tempero, MGI Pharma's chairman and CEO, stated, "Receiving orphan drug designation for Salagen as a treatment for Sjogren's Syndrome further enhances the potential of the drug to help people suffering from chronic dry mouths and eyes. We are currently evaluating various development options for the drug."
 In February 1992, MGI Pharma submitted a New Drug Application (NDA) to the FDA for Salagen as a treatment for radiation-induced xerostomia. Salagen was designated an orphan drug for this indication in September 1990. Additionally, MGI Pharma acquired rights to a patent to use Salagen in a mouthwash formulation to treat dry mouth in September 1991.
 MGI Pharma, Inc., acquires, develops, and markets pharmaceuticals prescribed and recommended by physician specialists. The company currently sells DIDRONEL(R) I.V. Infusion and Oratect(TM) Gel.
 -0- 3/9/91
 /CONTACT: Lori Weiman of MGI Pharma, 612-939-4666/
 (MOGN) CO: MGI Pharma, Inc. ST: Minnesota IN: MTC SU:


DS -- MN006 -- 6260 03/09/92 09:35 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 9, 1992
Words:278
Previous Article:NEW PRESIDENT ELECTED AT CORE INDUSTRIES INC
Next Article:UNI-MARTS, INC. DECLARES QUARTERLY CASH DIVIDEND
Topics:


Related Articles
MGI PHARMA CHEMOPROTECTIVE (MGI 136) PROGRAM REMAINS ON TRACK; COMPANY COMMENTS ON FDA ADVISORY COMMITTEE MEETING ON ETHYOL(R)
MGI PHARMA SUBMITS NEW DRUG APPLICATION FOR SALAGEN(TM)
MGI PHARMA ACQUIRES RIGHTS TO POTENTIAL NEW DRUG FOR CHRONIC DRY MOUTH; PRODUCT IN EARLY STAGE OF DEVELOPMENT
MGI PHARMA ACQUIRES EARLY STAGE COMPOUNDS WITH POTENTIAL TO BECOME BREAKTHROUGH ANTI-CANCER TREATMENT
MGI PHARMA'S SALAGEN(R) TABLETS "APPROVABLE" BY FDA; PRODUCT TREATS RADIATION-INDUCED DRY MOUTH IN HEAD AND NECK CANCER PATIENTS
MGI PHARMA, INC., ANNOUNCES APPROVAL OF SALAGEN TABLETS IN FRANCE, IRELAND AND GREECE
MGI Pharma, Inc. Completes Clinical Trials Agreement with the National Cancer Institute to Codevelop Cancer Drug
Positive Results from Clinical Studies with Salagen Tablets in Sjogren's Syndrome Patients Presented at International Dry Eye Conference
MGI Pharma Submits Supplemental New Drug Application For Salagen Tablets
MGI Pharma Updates Shareholders on Advancement of Cancer Therapy and Recent Product Launch at 1998 Annual Meeting

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters